within Pharmacolibrary.Drugs.ATC.J;

model J01DE02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 4.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Cefpirome is a fourth-generation cephalosporin antibiotic that is used to treat severe bacterial infections including those caused by Gram-negative and some Gram-positive organisms. It is administered intravenously, primarily in hospital settings for complicated infections. Although widely used in some regions, in others its clinical use is limited or discontinued.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single intravenous infusion.</p><h4>References</h4><ol><li><p>Nakayama, I, et al., &amp; Takase, K (1992). Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers. <i>Journal of clinical pharmacology</i> 32(3) 256–266. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1992.tb03834.x&quot;>10.1002/j.1552-4604.1992.tb03834.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1564130/&quot;>https://pubmed.ncbi.nlm.nih.gov/1564130</a></p></li><li><p>Strenkoski, LC, &amp; Nix, DE (1993). Cefpirome clinical pharmacokinetics. <i>Clinical pharmacokinetics</i> 25(4) 263–273. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325040-00002&quot;>10.2165/00003088-199325040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8261711/&quot;>https://pubmed.ncbi.nlm.nih.gov/8261711</a></p></li><li><p>Kang, S, et al., &amp; Chang, MJ (2020). Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation. <i>Antimicrobial agents and chemotherapy</i> 64(5) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00249-20&quot;>10.1128/AAC.00249-20</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32122899/&quot;>https://pubmed.ncbi.nlm.nih.gov/32122899</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01DE02;
